These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 17705693)

  • 1. Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes.
    Guevara-Aguirre J; Guevara-Aguirre M; Saavedra J; Bernstein G; Rosenbloom AL
    Diabetes Technol Ther; 2007 Aug; 9(4):372-6. PubMed ID: 17705693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Jan; 23(1):46-52. PubMed ID: 16409565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG; Gebbie J; Home PD
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study.
    Bolli GB; Kerr D; Thomas R; Torlone E; Sola-Gazagnes A; Vitacolonna E; Selam JL; Home PD
    Diabetes Care; 2009 Jul; 32(7):1170-6. PubMed ID: 19389820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.
    Hamann A; Matthaei S; Rosak C; Silvestre L;
    Diabetes Care; 2003 Jun; 26(6):1738-44. PubMed ID: 12766103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
    Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
    Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial.
    Garg SK; Mathieu C; Rais N; Gao H; Tobian JA; Gates JR; Ferguson JA; Webb DM; Berclaz PY
    Diabetes Technol Ther; 2009 Sep; 11 Suppl 2():S5-S16. PubMed ID: 19772449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Basal insulin substitution with glargine or continuous subcutaneous insulin infusion in adult type 1 diabetes patients-a randomized controlled trial.
    Bragd J; von Döbeln A; Lins PE; Adamson U; Bergström J; Oskarsson P
    Diabetes Technol Ther; 2010 Sep; 12(9):689-93. PubMed ID: 20687863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy.
    Heptulla RA; Allen HF; Gross TM; Reiter EO
    Pediatr Diabetes; 2004 Mar; 5(1):10-5. PubMed ID: 15043684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.
    Doyle EA; Weinzimer SA; Steffen AT; Ahern JA; Vincent M; Tamborlane WV
    Diabetes Care; 2004 Jul; 27(7):1554-8. PubMed ID: 15220227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.
    Lepore G; Dodesini AR; Nosari I; Trevisan R
    Diabetes Care; 2003 Apr; 26(4):1321-2. PubMed ID: 12663625
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes.
    Deiss D; Kordonouri O; Hartmann R; Hopfenmüller W; Lüpke K; Danne T
    Pediatr Diabetes; 2007 Jun; 8(3):157-62. PubMed ID: 17550426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lunch and bedtime NPH insulin plus mealtime insulin Lispro therapy with premeal regular insulin plus bedtime NPH insulin therapy in type 2 diabetes.
    Sargin H; Sargin M; Altuntaş Y; Sengül AM; Orbay E; Seber S; Uçak S; Yayla A
    Diabetes Res Clin Pract; 2003 Nov; 62(2):79-86. PubMed ID: 14581144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.